CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-05 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −104,467 | $30.30 | $3.2M | 69,302 |
| 2026-03-05 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise · Option (right to buy) 10b5-1 | −104,467 | 715,762 | ||
| 2026-03-02 | Davidson Michael H. Chief Executive Officer | Option exercise | +443,707 | 617,851 | ||
| 2026-03-02 | Davidson Michael H. Chief Executive Officer | Sale | −443,707 | $33.25 | $14.8M | 174,144 |
| 2026-03-02 | Davidson Michael H. Chief Executive Officer | Option exercise · Option (right to buy) | −443,707 | 239,267 | ||
| 2026-02-26 | Davidson Michael H. Chief Executive Officer | Option exercise 10b5-1 | +183,332 | 643,191 | ||
| 2026-02-26 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −165,408 | $33.63 | $5.6M | 477,783 |
| 2026-02-26 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −17,924 | $34.44 | $617K | 174,144 |
| 2026-02-26 | Davidson Michael H. Chief Executive Officer | Option exercise · Option (right to buy) 10b5-1 | −183,332 | 682,974 | ||
| 2026-02-25 | Davidson Michael H. Chief Executive Officer | Option exercise 10b5-1 | +58,253 | 518,112 | ||
| 2026-02-25 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −46,517 | $35.11 | $1.6M | 471,595 |
| 2026-02-25 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −10,436 | $35.96 | $375K | 461,159 |
| 2026-02-25 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −1,300 | $36.68 | $48K | 459,859 |
| 2026-02-25 | Davidson Michael H. Chief Executive Officer | Option exercise · Option (right to buy) 10b5-1 | −58,253 | 866,306 | ||
| 2026-02-24 | Davidson Michael H. Chief Executive Officer | Option exercise 10b5-1 | +64,708 | 524,567 | ||
| 2026-02-24 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −61,547 | $36.13 | $2.2M | 463,020 |
| 2026-02-24 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −3,161 | $36.46 | $115K | 459,859 |
| 2026-02-24 | Davidson Michael H. Chief Executive Officer | Option exercise · Option (right to buy) 10b5-1 | −64,708 | 924,559 | ||
| 2026-02-20 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale | −14,692 | $35.00 | $514K | 84,289 |
| 2026-02-20 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale | −30,789 | $35.46 | $1.1M | 53,500 |
Page 3 of 15 · 300 trades